Author: Sedykh, Sergey E; Prinz, Victor V; Buneva, Valentina N; Nevinsky, Georgy A
Title: Bispecific antibodies: design, therapy, perspectives Document date: 2018_1_22
ID: j897sql0_4
Snippet: To date, two BsAbs have been approved for use in the US (blinatumomab; Amgen) and Europe (catumaxomab; Trion Pharma). More than 60 drugs are in preclinical and 30 in clinical trials, and two-thirds of them are focused on cancer treatment. 16 Two therapeutic BsAbs that are on the market and some of the drugs in clinical and preclinical trials bring T lymphocytes (or natural killers) closer to cells expressing specific antigens on the surface, or s.....
Document: To date, two BsAbs have been approved for use in the US (blinatumomab; Amgen) and Europe (catumaxomab; Trion Pharma). More than 60 drugs are in preclinical and 30 in clinical trials, and two-thirds of them are focused on cancer treatment. 16 Two therapeutic BsAbs that are on the market and some of the drugs in clinical and preclinical trials bring T lymphocytes (or natural killers) closer to cells expressing specific antigens on the surface, or simultaneously bind two antigens on the surface of a target cell.
Search related documents:
Co phrase search for related documents- antigen bind and simultaneously antigen bind: 1
- antigen bind and specific antigen: 1, 2, 3, 4, 5, 6, 7, 8
- antigen bind and target cell: 1
- cancer treatment and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cancer treatment and natural killer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- cancer treatment and specific antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- cancer treatment and specific antigen express: 1
- cancer treatment and target cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- cancer treatment and target cell surface: 1, 2
- clinical trial and natural killer: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical trial and preclinical clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and specific antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- clinical trial and target cell: 1, 2, 3
- natural killer and specific antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- natural killer and specific antigen express: 1
- natural killer and target cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- natural killer and target cell surface: 1, 2, 3, 4, 5
- preclinical clinical trial and target cell: 1
- simultaneously antigen bind and specific antigen: 1
Co phrase search for related documents, hyperlinks ordered by date